Jefferies Group LLC assumed coverage on shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) in a report issued on Friday. The firm issued a buy rating and a $8.00 target price on the biotechnology company’s stock.
A number of other research analysts have also recently weighed in on SPPI. HC Wainwright reiterated a buy rating and issued a $10.00 target price on shares of Spectrum Pharmaceuticals in a report on Friday, November 4th. Zacks Investment Research cut Spectrum Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, October 28th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $8.50.
Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) opened at 5.67 on Friday. Spectrum Pharmaceuticals has a 12 month low of $3.21 and a 12 month high of $7.74. The stock’s market capitalization is $449.65 million. The company’s 50 day moving average price is $4.71 and its 200 day moving average price is $4.82.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last issued its earnings results on Monday, November 14th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.08. Spectrum Pharmaceuticals had a negative return on equity of 13.92% and a negative net margin of 34.19%. Equities analysts anticipate that Spectrum Pharmaceuticals will post ($1.00) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This report was originally posted by sleekmoney and is owned by of sleekmoney. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The legal version of this report can be viewed at http://sleekmoney.com/spectrum-pharmaceuticals-inc-sppi-now-covered-by-analysts-at-jefferies-group-llc/1658134.html.
Several hedge funds have recently made changes to their positions in the company. Two Sigma Securities LLC acquired a new stake in shares of Spectrum Pharmaceuticals during the third quarter worth about $101,000. Hartford Investment Management Co. raised its stake in shares of Spectrum Pharmaceuticals by 35.8% in the third quarter. Hartford Investment Management Co. now owns 24,300 shares of the biotechnology company’s stock worth $113,000 after buying an additional 6,400 shares during the last quarter. Campbell & CO Investment Adviser LLC raised its stake in shares of Spectrum Pharmaceuticals by 26.2% in the third quarter. Campbell & CO Investment Adviser LLC now owns 29,596 shares of the biotechnology company’s stock worth $138,000 after buying an additional 6,146 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Spectrum Pharmaceuticals by 15.6% in the third quarter. Louisiana State Employees Retirement System now owns 31,200 shares of the biotechnology company’s stock worth $146,000 after buying an additional 4,200 shares during the last quarter. Finally, Quantitative Systematic Strategies LLC raised its stake in shares of Spectrum Pharmaceuticals by 4.3% in the second quarter. Quantitative Systematic Strategies LLC now owns 24,942 shares of the biotechnology company’s stock worth $164,000 after buying an additional 1,039 shares during the last quarter. 69.31% of the stock is currently owned by institutional investors and hedge funds.
About Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/spectrum-pharmaceuticals-inc-sppi-now-covered-by-analysts-at-jefferies-group-llc/1658134.html
Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.